GenVec Reports Positive Interim Survival Data For TNFerade In Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Results presented at American Society of Clinical Oncology annual meeting show significant advantage in median survival versus standard care alone.
You may also be interested in...
Genvec May Partner TNFerade
Phase II/III pancreatic cancer trial goes on, but firm may need help to push indications such esophageal cancer.
Genvec May Partner TNFerade
Phase II/III pancreatic cancer trial goes on, but firm may need help to push indications such esophageal cancer.
GenVec Eyes BLA Submission for Pancreatic Cancer Therapy In 2008
FDA clears GenVec's Phase II/III trial for the gene-based oncologic TNFerade.